At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 20 enrolled
Drug / intervention
4mg fesoterodine +3 moredrug
Likely dose
4mg fesoterodinefrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 4 Way Placebo And Active Controlled Study To Evaluate The Effects Of Fesoterodine On Cognitive Function In Healthy Elderly Subjects
In Brief
A Phase 1 clinical trial evaluating 4mg fesoterodine, 8mg fesoterodine, and 2 other interventions for Healthy. Completed, enrolled 20 participants across 2 sites.
Detailed Summary
The study is designed to evaluate elements of cognitive function in subjects receiving either fesoterodine or alprazolam.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2010
First PostedJul 2010
Primary CompletionSep 2010
TodayJul 2026
First PostedJul 13, 2010
Enrollment StartJul 1, 2010
Primary CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 16.0 years ago
Interventions
4mg fesoterodinedrug
4mg tablet once daily for 6 days
8mg fesoterodinedrug
4mg tablet once daily for 3 days followed by 8mg tablet once daily for 3 days
alprazolam 1mgdrug
1mg tablet once on last day of treatment period at clinic
Placebodrug
Placebo tablet for fesoterodine once daily for 6 days and placebo tablet for alprazolam once on last day of treatment period at clinic